Compare Super Micro Computer Inc (SMCI) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Super Micro Computer Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Super Micro Computer Inc trades at $41.86 (market cap $28.10B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: Super Micro Computer Inc is far larger — about 2.8× State Street SPDR S&P Biotech ETF's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Super Micro Computer Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Super Micro Computer Inc for 19 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| SMCI | XBI | |
|---|---|---|
Market Cap | $28.10B | $10.11B |
Volume | 38,581,805 | 12,903,266 |
Sector | Technology | Broad Market / Factor |
52-Week High | $57.98 | $169.55 |
52-Week Low | $20.53 | $104.99 |
Typical Hold Time | 19 Days | 38 Days |
Enterprise Value | $33.56B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Super Micro Computer (SMCI) trades at $42.77, down 4.85% on the day, with a bullish technical signal and strong fundamental performance. Recent earnings beats and robust revenue growth to $39.1B in 2026 highlight its AI infrastructure strength. The stock is near its consensus price target of $42.33, with support at $42 and resistance at $44.
Outlook remains positive driven by AI server demand, though risks include margin pressure and a DOJ investigation. Analysts are mixed with 36% buy ratings, but the low P/E of 13.12 offers value if growth sustains. Investors should weigh execution risks against the company's strategic position in expanding AI markets.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Super Micro Computer Inc
Super Micro Computer, Inc., commonly known as Supermicro, is a leading provider of high-performance and high-efficiency server technology and innovation. The company specializes in designing, manufacturing, and selling advanced server, storage, and networking solutions, primarily for data centers, cloud computing, artificial intelligence, and 5G/Edge computing markets. SMCI's modular architecture allows for the rapid delivery of customized and purpose-built solutions, making it a key player in the enterprise computing and specialized AI infrastructure space.
Read more on SMCI →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
